New hope for advanced lung cancer patients in global drug trial
NCT ID NCT07365319
Summary
This global study is testing whether adding an experimental drug called EIK1001 to standard immunotherapy and chemotherapy can better control advanced lung cancer. It will involve 750 adults with stage 4 non-small cell lung cancer who have not yet received treatment for their advanced disease. The main goals are to see if the new combination helps patients live longer without their cancer getting worse and is safe to use.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE 4 NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.